Thomas Hofmarcher: My recent working paper on oncology medicines

Thomas Hofmarcher shared a post on LinkedIn:

”Let’s take a closer look at my recent working paper with the OECD – OCDE on oncology medicines. In the next days, I will feature key graphs that support some of our most important findings.

Finding (1/5): As the number of oncology medicines grows and prices rise, the budget impact of new cancer treatments is increasingly influencing reimbursement decisions in OECD countries, making it harder for some to provide fast access to these critical medicines.

Read the full report here.”

Source: Thomas Hofmarcher/LinkedIn

Thomas Hofmarcher is the Research Director at IHE – The Swedish Institute for Health Economics. He focuses on enhancing patient outcomes while taking fiscal realities into account.